Q4 2024 Management View The CEO highlighted that 2024 ended with SUBLOCADE achieving 20% net revenue growth despite challenges, including competition in the U.S. long-acting injectable (LAI) market ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback